Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Xeris Pharmaceuticals Inc
2B30Current price
2.24 EUR
0 EUR (0.00%)
Last closed
2.53 USD
Company
www.xerispharma.com
ISIN
US98422E1038
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
418 687 200 USD
Yield for 12 month
+17.29 %
1Y
3Y
5Y
10Y
15Y
2B30
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 180 North LaSalle Street, Chicago, IL, United States, 60601
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.67 USDP/E ratio
–Dividend Yield
–Current Year
+163 914 000 USD
Last Year
+110 248 000 USD
Current Quarter
+48 065 000 USD
Last Quarter
+40 638 000 USD
Current Year
+124 426 000 USD
Last Year
+87 614 000 USD
Current Quarter
+37 565 000 USD
Last Quarter
+31 956 000 USD
Key Figures 2B30
1 year
3 years
5 years
10 years
EBITDA
-24 999 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-7.04 %
PEG Ratio
–
Return On Equity TTM
-617.16 %
Wall Street Target Price
4.67 USD
Revenue TTM
181 412 992 USD
Book Value
-0.13 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
26.5 %
Dividend Yield
–
Gross Profit TTM
87 614 000 USD
Earnings per share
-0.42 USD
Diluted Eps TTM
-0.42 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-32.83 %
Dividend Analytics 2B30
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2B30
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:1
Payout Ratio
–
Last Split Date
06.10.2021
Dividend Date
–
Stock Valuation 2B30
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3.3676
Price Sales TTM
2.3079
Enterprise Value EBITDA
-3.3581
Price Book MRQ
3.3354
Financials 2B30
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2B30
For 52 weeks
1.46 USD
3.26 USD
50 Day MA
2.43 USD
Shares Short Prior Month
11 222 491
200 Day MA
2.28 USD
Short Ratio
7
Shares Short
10 809 571
Short Percent
7.43 %
BeatStart